ASLAN Pharmaceuticals Announces $5 Million Registered Direct Offering
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/29/2026
- Wall Street ends higher as Fed holds key rate steady, focus turns to earnings
- SK Hynix shares surge after Q3 profit beats expectations
- Oil prices rise on Yemen fighting, Saudi refinery attack
- Alphabet stock rises as OpenAI plans to buy Google's TPUs
- Wendy's shares surge 16% on $1.4 billion takeover bid by Nelson Peltz’s Trian Fund
- ServiceNow (NOW) Misses Q3 EPS by 2c, Beats on Revenue; Offers Q4 Revenue Guidance
- Oracle sets $225 billion revenue target for FY30 at investor day
- Rivian shares slip ahead of Thursday earnings release
- Marvell in advanced talks to acquire Lumentum, Bloomberg reports
- SpaceX stock drops amid spaceport lawsuit, debt concerns
Aslan Pharma (ASLN) PT Lowered to $10 at Piper Sandler
March 13, 2024 6:41 AM EDTPiper Sandler analyst Edward A. Tenthoff lowered the price target on Aslan Pharma (NASDAQ: ASLN) to $10.00 (from $15.00) while maintaining a Overweight rating.
The analyst comments "Aslan ended 3Q:23 with cash of $40.8 million and debt of $38 million. The company issued 5 million and 5 million warrants... More



